Clinton Lewis - Zoetis President

ZTS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  President
Mr. Clinton A. Lewis, Jr. is Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics of the Company. Mr. Lewis has served as our Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics and Aquatic Health since March 2018, and was given responsibility for Human Medical Diagnostics in January 2019. He previously served as our Executive Vice President and President, International Operations from May 2015 to February 2018. From October 2012 through April 2015, he served as our Executive Vice President and President of U.S. Operations, and from 2007 to 2012, he was President of U.S. Operations for Pfizer Animal Health, our predecessor company. Mr. Lewis joined Pfizer in 1988 and held various positions across sales, marketing and general management, including Senior Vice President of Sales, U.S. General Manager, Pfizer Caribbean and General Manager, U.S. AntiInfectives.
Age: 51  President Since 2018      
973 822-7000  www.zoetis.com
Lewis holds a bachelor degree in biology from Fairfield University and a MBA in marketing from Fairleigh Dickinson University.

Clinton Lewis Latest Insider Activity

Management Efficiency

The company has Return on Asset of 11.71 % which means that on every $100 spent on asset it made $11.71 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 60.93 % implying that it generated $60.93 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Amit SachdevVertex Pharmaceuticals Incorpor
2017
K RaoDr Reddys Laboratories Ltd
2016
Peter PowchikRegeneron Pharmaceuticals
2006
Samiran DasDr Reddys Laboratories Ltd
2016
Michael PariniVertex Pharmaceuticals Incorpor
2017
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
James DillardPerrigo Company Plc
2019
Ganadhish KamatDr Reddys Laboratories Ltd
2016
James MichaudPerrigo Company Plc
2016
Amit BiswasDr Reddys Laboratories Ltd
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Michael AbermanRegeneron Pharmaceuticals
2015
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Jeffrey NeedhamPerrigo Company Plc
2009
Svend AndersenPerrigo Company Plc
2017
Paul SilvaVertex Pharmaceuticals Incorpor
2019
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Joseph LaRosaRegeneron Pharmaceuticals
2019
John GrayVertex Pharmaceuticals Incorpor
2019

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run ETF Directory Now

   

ETF Directory

Find actively-traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 182.01
Purchased few shares of
few hours ago
Traded for 1345.02
Purchased over 40 shares of
few hours ago
Traded for 64.33
See also Your Current Watchlist. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com